Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GE Healthcare announces Draximage Sestamibi distribution agreement

GE Healthcare announces Draximage Sestamibi distribution agreement

24th December 2007

GE Healthcare has signed an agreement with Draximage, a division of Draxis Health, to distribute the Draximage Sestamibi system.

Under the terms of the deal, GE Healthcare will become the exclusive distributor of Draximage Sestamibi following the expiration of its primary innovator patent and its approval by the US Food and Drug Administration.

The system is currently under review by the regulator following its submission for approval in February 2007.

John Chiminski, president and chief executive officer of the medical diagnostics division at GE Healthcare, said: “Nuclear cardiology is a proven technology and we’re confident that our partnership with Draximage will expand the access to and applicability of these procedures when and where they are needed.”

He added that this agreement highlights the firm’s dedication to nuclear medicine, underlining its strong performance in radiopharmacy and the breadth of its portfolio in this field.

Mr Chiminski notes that GE Healthcare developed the Myoview kit used for the preparation of Technetium Tc99m Tetrofosmin for injection.

The company reports that Technetium-labelled radiopharmaceuticals are used in around nine out of ten nuclear medicine studies in the detection of coronary artery disease.

In June 2006, GE Healthcare announced the launch of the Xeleris 2 advanced nuclear medicine workstation that facilitates the retrieval of nuclear medicine images by clinicians from PCs located around a hospital.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.